December 19, 2016 : SGLT-2 Inhibitors: 2016 Year in Review

2016 brought us a near-constant stream of news about SGLT-2 Inhibitors, from their role in combination therapies to their cardiovascular benefits. Here are the ten SGLT-2 items that most engaged you this year.

January:

• Empagliflozin/Linagliptin Combination with Metformin for Triple Therapy

February:

• Empagliflozin Potentially Protects Pancreatic Beta-cells in T1DM
• Shifting Paradigm in Diabetes Treatment – An Interview with Dr. Vinik

April:

• Europe Agrees: Learn the Signs of Atypical DKA in Patients Using SGLT-2s

May:

• AACE/ACE Position Statement On SGLT-2 Inhibitors and DKA Risk

June:

• SGLT-2 Inhibitors in the Spotlight at ADA
• More Good News for Empagliflozin

July:

• Invokana Superior As Second Add-on to Metformin

September: 

• Type I Diabetes Mellitus: A Triple Therapy Approach

October:

• What to Do If Metformin Fails To Get Patients To Target

When we began 2016, we were just starting to see the value of the SGLT-2 Inhibitors gain momentum. In fact, our first feature of the year looked at mixing an SGLT-2 Inhibitor with a DPP-4i and Metformin to maximize glucose control, and over the year we reviewed over 40 articles and studies on the SGLT-2 Inhibitors.

Our publisher, Steve Freed, worked with our entire staff to isolate the best of SGLT-2 Inhibitors in 2016. Take a look at these features below and see if you think you can increase your knowledge by reading the best of the best.

Dave Joffe

Editor-in-chief

A year after the FDA warning, a strong response to the question: are SGLT-2 inhibitors safe?

New study indicates canagliflozin superior to glimepiride in lowering A1C.

European committee affirms benefits of SGLT-2s while urging healthcare providers to be vigilant and educate patients for signs and symptoms of atypical DKA.

Two pills provided greater glucose-lowering efficacy than three with low hypoglycemia risk.

New animal study shows the effects of empagliflozin, an SGLT-2 inhibitor, on the pancreatic cells of mice.

At the 2016 conference in New Orleans, the latest research on SGLT-2 Inhibitors was on display.

How SGLT-2 inhibitors can provide new approach over treatment centered on attaining glycemic control, intensive therapy.

Study announces a new benefit in addition to reductions in major adverse cardiovascular events.

What are the benefits of dapagliflozin for type 1 when added to an insulin-liraglutide regimen?

Combination therapy resulting in superior glycemic control, weight loss versus either agent alone